Physician profile
Lou W Alexandre
NPI 1457020943
$4,778.59
in general payments reported to CMS, 2019-2025
32 companies · $1,232 in 2025
The $1,232 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $94.70 · 2022: $884 · 2023: $1,108 · 2024: $1,459 · 2025: $1,232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,800.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $783.23 | 2022-2025 | |
| Novo Nordisk INC | $734.39 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $700.70 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $487.83 | 2023-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $258.45 | 2023-2025 | Camzyos, Eliquis, Zeposia |
| Merck Sharp & Dohme LLC | $250.94 | 2023-2025 | Verquvo, Lynparza, Keytruda |
| Glaxosmithkline, LLC. | $178.61 | 2021-2024 | Arexvy, Trelegy Ellipta, Zejula |
| Neurocrine Biosciences, INC. | $169.43 | 2023-2025 | Ingrezza, Ongentys |
| Cvrx, INC. | $161.52 | 2024 | Barostim Neo System |
| Argenx US, INC. | $156.75 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Abbott Laboratories | $144.99 | 2024 | Freestyle Libre 3 |
| Insulet Corporation | $139.84 | 2025 | Omnipod |
| Alexion Pharmaceuticals, INC. | $65.26 | 2023-2025 | Ultomiris |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $48.08 | 2023 | Lifevest |
| Biogen, INC. | $46.01 | 2024 | Vumerity, Tysabri |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $43.72 | 2021-2022 | |
| Neurelis, INC. | $41.85 | 2021-2025 | Valtoco |
| Alnylam Pharmaceuticals INC. | $41.74 | 2022 | |
| Bridgebio Pharma, INC. | $38.00 | 2025 | Attruby |
| Banner Life Sciences, LLC | $29.90 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $29.64 | 2025 | Austedo Xr |
| Sk Life Science, INC. | $28.67 | 2022 | |
| Janssen Pharmaceuticals, INC | $27.99 | 2022 | |
| Amgen INC. | $27.80 | 2022-2025 | Repatha |
| Otsuka America Pharmaceutical, INC. | $27.19 | 2023-2024 | Rexulti |
| Eisai INC. | $23.78 | 2021 | |
| Mylan Specialty L.P. | $17.70 | 2022 | |
| Celgene Corporation | $16.99 | 2024 | Zeposia |
| Lundbeck LLC | $15.62 | 2023 | Rexulti |
| Pfizer INC. | $15.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.75 | 2023 | Farxiga |
| Ucb, INC. | $13.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lou Alexandre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.